|
Primary (100) |
Primary (100) |
Secondary (51) |
|
|
|
Gender (female/male) |
63/37 |
45/6 |
45/6 |
61/10 |
41/49 |
41/49 |
Mean age (years ± SD) |
36.3±12.1 |
32.9±10.2 |
32.9±10.2 |
30.1±8.2 |
43.4±12.2 |
43.4±12.2 |
Clinical manifestations |
|
|
|
|
|
|
Thrombosis, n (%) |
80(80.0%) |
38(74.5%) |
38(74.5%) |
0 |
NA |
NA |
Pregnancy morbidity, n (%) |
33(33.0%) |
16(31.4%) |
16(31.4%) |
0 |
NA |
NA |
Thrombosis + pregnancy morbidity, n (%) |
13(13%) |
3(5.9%) |
3(5.9%) |
0 |
NA |
NA |
LA, n (%) |
73(73.0%) |
44(86.3%) |
44(86.3%) |
17(23.9%) |
NA |
NA |
History of arterial thrombosis, n (%) |
43(43.0%) |
21(41.2%) |
21(41.2%) |
0 |
NA |
NA |
Stroke, n (%) |
4(4.0%) |
2(3.9%) |
2(3.9%) |
0 |
NA |
NA |
Coronary heart disease, n (%) |
9(9.0%) |
2(3.8%) |
2(3.8%) |
0 |
NA |
NA |
Eye involvement, n(%) |
3(3.0%) |
1(2.0%) |
1(2.0%) |
|
|
|
Lower limb artery occlusion, n (%) |
1(1.0%) |
0 |
0 |
0 |
NA |
NA |
History of venous thrombosis, n (%) |
47(47.0%) |
24(47.1%) |
24(47.1%) |
0 |
NA |
NA |
Deep vein thrombosis, n (%) |
19(19.0%) |
7(13.7%) |
7(13.7%) |
0 |
NA |
NA |
Pulmonary embolism, n (%) |
19(19.0%) |
2(3.9%) |
2(3.9%) |
0 |
NA |
NA |
Upper limb vein thrombosis, n (%) |
0 |
1(2.0%) |
1(2.0%) |
0 |
NA |
NA |
Renal vein thrombosis, n (%) |
1(1.0%) |
0 |
0 |
0 |
NA |
NA |
Portal vein thrombosis, n (%) |
4(4.0%) |
1(2.0%) |
1(2.0%) |
0 |
NA |
NA |
Cerebral venous and sinus thrombosis, n (%) |
3(3.0%) |
1(2.0%) |
1(2.0%) |
0 |
NA |
NA |
Central retinal venous occlusion, n (%) |
1(1.0%) |
0 |
0 |
0 |
NA |
NA |
Microangiopathy, n (%) |
57(57%) |
24(47.1%) |
24(47.1%) |
0 |
NA |
NA |
TP, n (%) |
38(38%) |
*28(54.9%) |
*28(54.9%) |
21(29.6%) |
NA |
NA |
Heat valve disease, n (%) |
0 |
6(11.8%) |
6(11.8%) |
0 |
NA |
NA |
Non-stroke CNS manifestations, n (%) |
4(4.0%) |
4(7.8%) |
4(7.8%) |
0 |
NA |
NA |
Antiphospholipid syndrome nephropathy, n (%) |
6(6.0%) |
2(3.8%) |
2(3.8%) |
0 |
NA |
NA |
Autoimmune hemolytic anemia, n (%) |
1(1.0%) |
5(9.8%) |
5(9.8%) |
0 |
NA |
NA |
Thrombotic Microangiopathy, n (%) |
0 |
1(2.0%) |
1(2.0%) |
0 |
NA |
NA |
Hemolytic uremic syndrome, n (%) |
1(1.0%) |
0 |
0 |
0 |
NA |
NA |
History of adverse pregnancy, n (%) |
37(37%) |
20(39.2%) |
20(39.2%) |
4(5.6%) |
NA |
NA |
Early fetal loss (<10 weeks), n (%) |
12(12.0%) |
8(15.7%) |
8(15.7%) |
4(5.6%) |
NA |
NA |
Late fetal loss (10-28 weeks), n (%) |
19(19.0%) |
12(23.5%) |
12(23.5%) |
0 |
NA |
NA |
Placental insufficiency, n (%) |
14(14.0%) |
7(13.7%) |
7(13.7%) |
0 |
NA |
NA |